千金药业(600479.SH)前三季度净利润1.87亿元，同比增长11.47%

Core Viewpoint - Q3 2025 financial results of Qianjin Pharmaceutical (600479.SH) show modest growth in revenue and significant increase in net profit [1] Financial Performance - Total operating revenue for the first three quarters of 2025 reached 2.718 billion yuan, reflecting a year-on-year increase of 0.14% [1] - Net profit attributable to shareholders of the parent company was 187 million yuan, representing a year-on-year growth of 11.47% [1] - Basic earnings per share stood at 0.4477 yuan [1]